105 related articles for article (PubMed ID: 19890063)
21. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Röhrig UF; Majjigapu SR; Vogel P; Zoete V; Michielin O
J Med Chem; 2015 Dec; 58(24):9421-37. PubMed ID: 25970480
[TBL] [Abstract][Full Text] [Related]
22. Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase.
Rafice SA; Chauhan N; Efimov I; Basran J; Raven EL
Biochem Soc Trans; 2009 Apr; 37(Pt 2):408-12. PubMed ID: 19290871
[TBL] [Abstract][Full Text] [Related]
23. Dual-Blockade Immune Checkpoint for Breast Cancer Treatment Based on a Tumor-Penetrating Peptide Assembling Nanoparticle.
Li G; Gao Y; Gong C; Han Z; Qiang L; Tai Z; Tian J; Gao S
ACS Appl Mater Interfaces; 2019 Oct; 11(43):39513-39524. PubMed ID: 31599562
[TBL] [Abstract][Full Text] [Related]
24. What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?
Eleftheriadis T
Front Immunol; 2018; 9():1879. PubMed ID: 30150994
[No Abstract] [Full Text] [Related]
25. Folated pH-degradable nanogels for the simultaneous delivery of docetaxel and an IDO1-inhibitor in enhancing cancer chemo-immunotherapy.
Qiao H; Chen X; Chen E; Zhang J; Huang D; Yang D; Ding Y; Qian H; Feijen J; Chen W
Biomater Sci; 2019 Jun; 7(7):2749-2758. PubMed ID: 30997445
[TBL] [Abstract][Full Text] [Related]
26. Journal Honors Burles Johnson III, MD, PhD, As Recipient of the 2017 Journal of Clinical Oncology Young Investigator Award.
J Clin Oncol; 2017 Aug; 35(22):2457-2458. PubMed ID: 28594598
[No Abstract] [Full Text] [Related]
27. Regulatory dendritic cells: new targets for cancer immunotherapy.
Shurin MR; Naiditch H; Zhong H; Shurin GV
Cancer Biol Ther; 2011 Jun; 11(11):988-92. PubMed ID: 21474998
[No Abstract] [Full Text] [Related]
28. Making the tumor-specific effectors ineffective.
Levitsky V
Semin Cancer Biol; 2007 Aug; 17(4):265-6. PubMed ID: 17624803
[No Abstract] [Full Text] [Related]
29. Modulation of cancer-specific immune responses by amino acid degrading enzymes.
Timosenko E; Hadjinicolaou AV; Cerundolo V
Immunotherapy; 2017 Jan; 9(1):83-97. PubMed ID: 28000524
[TBL] [Abstract][Full Text] [Related]
30. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.
Muller AJ; Scherle PA
Nat Rev Cancer; 2006 Aug; 6(8):613-25. PubMed ID: 16862192
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of indoleamine 2,3-dioxygenase not only blocks autoreactive B cell activation, but it also reduces production of antibodies in general: comment on the article by Pigott and Mandik-Nayak.
Eleftheriadis T; Pissas G; Liakopoulos V; Stefanidis I
Arthritis Rheum; 2013 Jul; 65(7):1951-2. PubMed ID: 23529590
[No Abstract] [Full Text] [Related]
32. Anticancer effects of imatinib via immunostimulation.
Zitvogel L; Kroemer G
Nat Med; 2011 Sep; 17(9):1050-1. PubMed ID: 21900920
[No Abstract] [Full Text] [Related]
33. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
Basler M; Lauer C; Beck U; Groettrup M
J Immunol; 2009 Nov; 183(10):6145-50. PubMed ID: 19841190
[TBL] [Abstract][Full Text] [Related]
34. IDO inhibitors move center stage in immuno-oncology.
Sheridan C
Nat Biotechnol; 2015 Apr; 33(4):321-2. PubMed ID: 25850038
[No Abstract] [Full Text] [Related]
35. Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials.
Yuasa HJ; Ball HJ; Ho YF; Austin CJ; Whittington CM; Belov K; Maghzal GJ; Jermiin LS; Hunt NH
Comp Biochem Physiol B Biochem Mol Biol; 2009 Jun; 153(2):137-44. PubMed ID: 19402226
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of indoleamine 2,3-dioxygenase by thielavin derivatives from a soil fungus, Coniochaeta sp. 10F058.
Jang JP; Jang JH; Oh M; Son S; Kim SM; Kim HM; Shin KS; Oh H; Soung NK; Hong YS; Kim BY; Ahn JS
J Antibiot (Tokyo); 2014 Apr; 67(4):331-3. PubMed ID: 24326340
[No Abstract] [Full Text] [Related]
37. Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata.
Pereira A; Vottero E; Roberge M; Mauk AG; Andersen RJ
J Nat Prod; 2006 Oct; 69(10):1496-9. PubMed ID: 17067170
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A.
Carr G; Chung MK; Mauk AG; Andersen RJ
J Med Chem; 2008 May; 51(9):2634-7. PubMed ID: 18393489
[TBL] [Abstract][Full Text] [Related]
39. Plectosphaeroic acids A, B, and C, indoleamine 2,3-dioxygenase inhibitors produced in culture by a marine isolate of the fungus Plectosphaerella cucumerina.
Carr G; Tay W; Bottriell H; Andersen SK; Mauk AG; Andersen RJ
Org Lett; 2009 Jul; 11(14):2996-9. PubMed ID: 19537768
[TBL] [Abstract][Full Text] [Related]
40. Mathematical modelling of the synergistic combination of radiotherapy and indoleamine-2,3-dioxygenase (IDO) inhibitory immunotherapy against glioblastoma.
Chakwizira A; Ahlstedt J; Nittby Redebrandt H; Ceberg C
Br J Radiol; 2018 Jul; 91(1087):20170857. PubMed ID: 29688039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
